17:08 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; colorectal cancer; melanoma Mouse studies suggest combining the c-MET inhibitor capmatinib with immunotherapies could help treat melanoma, breast and colorectal cancers. In mouse models of c-MET-dependent and -independent melanoma, adoptive transfer of...
16:46 , Oct 20, 2017 |  BioCentury  |  Emerging Company Profile

One-upping c-MET

With a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V. is banking on the dual selectivity of its molecule and its algorithm for identifying responders to...
20:49 , Oct 13, 2017 |  BioCentury  |  Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
00:53 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of the HGF/SF / c-MET / Src and SHH / IGF-1 / IGF1R pathways could help treat pancreatic ductal adenocarcinoma (PDAC). In human PDAC...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Capmatinib: Phase II data

Data from 28 patients with advanced c-MET dysregulated HCC in the dose-expansion cohort of an open-label, Asian Phase II trial showed that twice-daily 600 mg oral capmatinib led to an ORR of 11%, including 3...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Capmatinib: Phase II data

Data from 65 evaluable adults with EGFR-mutated, c-MET-amplified NSCLC who progressed after single agent EGFR TKI therapy in the dose-expansion Phase II portion of an open-label, international Phase Ib/II trial showed that twice-daily 400 mg...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Binimetinib: Preliminary Phase II data

Preliminary data from 40 BRAF and MEK inhibitor-naive patients with locally advanced or metastatic BRAF V600 mutation-positive melanoma in Group A of Part 1 of the 2-part, open-label, international Phase II LOGIC2 trial showed that...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Encorafenib: Preliminary Phase II data

Preliminary data from 40 BRAF and MEK inhibitor-naive patients with locally advanced or metastatic BRAF V600 mutation-positive melanoma in Group A of Part 1 of the 2-part, open-label, international Phase II LOGIC2 trial showed that...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Bristol-Myers, Novartis deal

Bristol-Myers and Novartis partnered to run two Phase I/II trials to evaluate combinations of BMS's Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC). The Novartis therapies are Zykadia ceritinib, INC280...
02:24 , Oct 7, 2014 |  BC Extra  |  Company News

BMS, Novartis to test combinations for NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) and Novartis AG (NYSE:NVS; SIX:NOVN) have partnered to run two Phase I/II trials to evaluate combinations of BMS' Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC)....